Transpulmonary B-Type Natriuretic Peptide Uptake and Cyclic Guanosine Monophosphate Release in Heart Failure and Pulmonary HypertensionThe Effects of Sildenafil
Vojtech Melenovsky, MD, PhD*,
Hikmet Al-Hiti, MD,
Ludmila Kazdova, PhD,
Antonin Jabor, MD, PhD,
Petr Syrovatka, MD,
Ivan Malek, MD, PhD,
Jiri Kettner, MD, PhD and
Josef Kautzner, MD, PhD
Department of Cardiology, Institute of Clinical and Experimental Medicine–IKEM, Prague, Czech Republic
View larger version (10K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Pulmonary and Systemic Arterial Compliances and the Relation of PVR to Transpulmonary cGMP Release
(A) Pulmonary and systemic arterial compliance in HF patients with low or high PVR ( 200 or >200 dyn·s·cm–5), median ± interquartile range. (B) Correlation between PVR and transpulmonary cGMP release in L-PVR (green) and H-PVR (red) patients. cGMP = cyclic guanosine monophosphate; H = high; L = low; PVR = pulmonary vascular resistance.
|
|
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Transpulmonary BNP Uptake and cGMP Release
(A) Transpulmonary BNP uptake (median ± interquartile range) and cGMP release (mean ± SD) in HF patients with low or high PVR (200 or >200 dyn·s·cm-5). (B) Transpulmonary BNP uptake and cGMP release in the H-PVR group before and after administration of 40 mg of sildenafil. BNP = B-type natriuretic peptide; other abbreviations as in Figure 1.
|
|
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Hemodynamic Responses to Sildenafil
(A) Individual responses to 40 mg of sildenafil in H-PVR patients. Red lines = PGE1-irreversible PH; green lines = PGE1-reversible PH (partially or completely). (B) Relation of pulmonary arterial compliance to PVR before (red) and after (blue) sildenafil. PGE1 = prostaglandin E1; PH = pulmonary hypertension; other abbreviations as in Figure 1.
|
|
|
